FHA
MCRB icon

Flagship Harbor Advisors’s Seres Therapeutics MCRB Stock Holding History

Flagship Harbor Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-75
Closed -$6K – 1922
2019
Q3 		$6K Hold
75
– – ﹤0.01% 1437
2019
Q2 		$4K Hold
75
– – ﹤0.01% 1553
2019
Q1 		$10K Hold
75
– – ﹤0.01% 1298
2018
Q4 		$6K Hold
75
– – ﹤0.01% 1393
2018
Q3 		$11K Hold
75
– – ﹤0.01% 1378
2018
Q2 		$12K Buy
+75
New +$12.3K ﹤0.01% 1294

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Flagship Harbor Advisors's MCRB Position: Q4 2019 in Review

Flagship Harbor Advisors sold out of Seres Therapeutics (MCRB) in Q4 2019, closing a stake of 75 shares — an estimated $6K sold.

Flagship Harbor Advisors first reported a position in MCRB in Q2 2018 and held it in 6 quarters. The position peaked at $12K in Q2 2018. 79 funds tracked by Wall St. Rank hold MCRB as of Q4 2019.

  • Flagship Harbor Advisors reported no remaining Seres Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Flagship Harbor Advisors sold 75 Seres Therapeutics shares in Q4 2019, an estimated $6K.
  • Flagship Harbor Advisors first reported a position in Seres Therapeutics in Q2 2018 and held it in 6 quarters.
  • Flagship Harbor Advisors's Seres Therapeutics position peaked at $12K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2019.

Based on Flagship Harbor Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.